- Home
- SWZ vs NRXP Comparison
SWZ vs NRXP Comparison
Compare SWZ & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWZ | NRXP |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SWZ | NRXP |
|---|---|---|
| Price | $6.21 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 114.9K | ★ 520.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.58 |
| 52 Week High | $9.43 | $3.84 |
Technical Indicators
Market Signals| Indicator | SWZ | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 44.48 |
| Support Level | $6.02 | $1.65 |
| Resistance Level | $6.22 | $2.79 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 99.94 | 52.54 |
Price Performance
Historical ComparisonAbout SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.